$ACHV
ACHIEVE LIFE SCIENCES, INC.

2014 Q4 Form 10-Q Financial Statement

#000119312514389643 Filed on October 30, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q4
Revenue $5.650M $4.800M $8.600M
YoY Change -34.3% -51.32% -12.07%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.730M $2.460M $2.450M
YoY Change 11.43% -0.4% 20.1%
% of Gross Profit
Research & Development $9.852M $9.586M $13.20M
YoY Change -25.34% -46.76% -15.66%
% of Gross Profit
Depreciation & Amortization $50.00K $60.00K $70.00K
YoY Change -28.57% 0.0% 133.33%
% of Gross Profit
Operating Expenses $9.852M $12.05M $13.20M
YoY Change -25.34% -33.1% -15.66%
Operating Profit
YoY Change
Interest Expense $20.00K $0.00 $30.00K
YoY Change -33.33% -100.0% -57.14%
% of Operating Profit
Other Income/Expense, Net $983.0K $2.335M $359.0K
YoY Change 173.82% 316.22% -83.28%
Pretax Income -$5.680M -$4.910M -$6.680M
YoY Change -14.97% -51.14% 62.93%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.682M -$4.907M -$6.678M
YoY Change -14.91% -51.19% 62.76%
Net Earnings / Revenue -100.57% -102.23% -77.65%
Basic Earnings Per Share
Diluted Earnings Per Share -$568.0M -$491.0M -$668.0M
COMMON SHARES
Basic Shares Outstanding 21.28M shares 21.14M shares 14.71M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $47.06M $54.00M $39.20M
YoY Change 20.04% 15.38% -48.01%
Cash & Equivalents $27.90M $48.95M $14.59M
Short-Term Investments $19.16M $5.100M $24.60M
Other Short-Term Assets $499.0K $2.500M $5.800M
YoY Change -91.4% -7.41% 52.63%
Inventory
Prepaid Expenses $5.770M
Receivables $5.676M $4.827M $8.657M
Other Receivables $100.0K $0.00 $200.0K
Total Short-Term Assets $55.76M $61.32M $53.87M
YoY Change 3.52% 2.69% -32.82%
LONG-TERM ASSETS
Property, Plant & Equipment $257.0K $312.0K $397.0K
YoY Change -35.26% -29.57% 7.01%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $273.0K $773.0K $1.111M
YoY Change -75.43% -34.21% -3.56%
Total Long-Term Assets $530.0K $1.336M $1.822M
YoY Change -70.91% -30.85% -0.82%
TOTAL ASSETS
Total Short-Term Assets $55.76M $61.32M $53.87M
Total Long-Term Assets $530.0K $1.336M $1.822M
Total Assets $56.29M $62.65M $55.69M
YoY Change 1.08% 1.64% -32.1%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $72.00K $1.562M $139.0K
YoY Change -48.2% 3905.13% -89.54%
Accrued Expenses $15.70M $13.17M $11.78M
YoY Change 33.23% 16.17% 181.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $200.0K $1.100M $1.100M
YoY Change -81.82% 0.0% 0.0%
Total Short-Term Liabilities $22.22M $20.93M $14.93M
YoY Change 48.77% 45.65% 29.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $2.900M $3.500M
YoY Change -100.0% -21.62% -18.6%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $2.900M $3.500M
YoY Change -100.0% -21.62% -18.6%
TOTAL LIABILITIES
Total Short-Term Liabilities $22.22M $20.93M $14.93M
Total Long-Term Liabilities $0.00 $2.900M $3.500M
Total Liabilities $22.23M $23.80M $18.48M
YoY Change 20.32% 31.52% 16.88%
SHAREHOLDERS EQUITY
Retained Earnings -$160.0M -$154.3M -$133.7M
YoY Change 19.65% 21.47% 31.27%
Common Stock $191.4M $190.5M $168.3M
YoY Change 13.75% 13.44% 1.72%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $34.06M $38.85M $37.21M
YoY Change
Total Liabilities & Shareholders Equity $56.29M $62.65M $55.69M
YoY Change 1.08% 1.64% -32.1%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q4
OPERATING ACTIVITIES
Net Income -$5.682M -$4.907M -$6.678M
YoY Change -14.91% -51.19% 62.76%
Depreciation, Depletion And Amortization $50.00K $60.00K $70.00K
YoY Change -28.57% 0.0% 133.33%
Cash From Operating Activities -$6.950M -$5.760M -$7.540M
YoY Change -7.82% -43.7% -20.55%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$10.00K -$20.00K
YoY Change -100.0% -88.89%
Acquisitions
YoY Change
Other Investing Activities -$14.12M -$5.060M $9.200M
YoY Change -253.48% -214.74% -43.9%
Cash From Investing Activities -$14.12M -$5.070M $9.180M
YoY Change -253.81% -214.97% -43.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $24.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K 19.17M 0.000
YoY Change
NET CHANGE
Cash From Operating Activities -6.950M -5.760M -7.540M
Cash From Investing Activities -14.12M -5.070M 9.180M
Cash From Financing Activities 20.00K 19.17M 0.000
Net Change In Cash -21.05M 8.340M 1.640M
YoY Change -1383.54% -243.3% -75.67%
FREE CASH FLOW
Cash From Operating Activities -$6.950M -$5.760M -$7.540M
Capital Expenditures $0.00 -$10.00K -$20.00K
Free Cash Flow -$6.950M -$5.750M -$7.520M
YoY Change -7.58% -43.79% -19.23%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12950000
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
21290093 shares
CY2014Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
300000
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
21000
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
21280867 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.77
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1285862 shares
CY2014Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
3975000
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
20927000
CY2014Q3 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
2873000
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2637000
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1562000
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-154276000
CY2014Q3 us-gaap Guarantee Obligations Current Carrying Value
GuaranteeObligationsCurrentCarryingValue
0
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2462000
CY2014Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
251000
CY2014Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
19000
CY2014Q3 us-gaap Assets
Assets
62651000
CY2014Q3 us-gaap Short Term Investments
ShortTermInvestments
5057000
CY2014Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
190469000
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13167000
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
38851000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
100000
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
62651000
CY2014Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3975000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
75000
CY2014Q3 us-gaap Liabilities
Liabilities
23800000
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1109000
CY2014Q3 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
1114000
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
25000
CY2014Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
48950000
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3200000
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
312000
CY2014Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
54258000
CY2014Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
5061000
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4827000
CY2014Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
4000
CY2014Q3 us-gaap Cash
Cash
17934000
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
773000
CY2014Q3 us-gaap Assets Current
AssetsCurrent
61315000
CY2014Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
5057000
CY2014Q3 ogxi Indemnification Expense
IndemnificationExpense
0
CY2014Q3 ogxi Common Stock Sales Agreement Net Amount
CommonStockSalesAgreementNetAmount
22000000
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
21280867 shares
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18075000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14707886 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14707886 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
11.39
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1007491 shares
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
214000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
14934000
CY2013Q4 us-gaap Capital Lease Obligations Noncurrent
CapitalLeaseObligationsNoncurrent
3544000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
15000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2643000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
139000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-133689000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
168242000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11784000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
37211000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
55689000
CY2013Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
214000
CY2013Q4 us-gaap Liabilities
Liabilities
18478000
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1705000
CY2013Q4 us-gaap Capital Lease Obligations Current
CapitalLeaseObligationsCurrent
1092000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14593000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0115 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y9M18D
CY2013Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2700000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
397000
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5770000
CY2013Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
314000
CY2013Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
218000
CY2013Q4 us-gaap Assets
Assets
55689000
CY2013Q4 us-gaap Short Term Investments
ShortTermInvestments
24629000
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8657000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1111000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
53867000
CY2014Q3 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
1600000
CY2014Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
24000000
CY2014Q3 ogxi Net Proceeds Received From Offering After Deducting Underwriting Discounts And Offering Expenses
NetProceedsReceivedFromOfferingAfterDeductingUnderwritingDiscountsAndOfferingExpenses
22400000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
100000
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-28389000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14675244 shares
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.72
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8702 pure
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2900000 shares
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
45869 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3475 shares
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
31615000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
3000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1019000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-32000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-25168000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3119000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
121000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
234000
us-gaap Net Income Loss
NetIncomeLoss
-25171000
us-gaap Investment Income Interest
InvestmentIncomeInterest
124000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
9208000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
3000
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
7000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-184000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
42122000
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-504000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
55096000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5125000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2874000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2100000
us-gaap Depreciation
Depreciation
162000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
10000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
7154000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
23247000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10000
us-gaap Costs And Expenses
CostsAndExpenses
49568000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7446000
us-gaap Share Based Compensation
ShareBasedCompensation
2490000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-1290000
ogxi Revenues From Collaborative Agreements
RevenuesFromCollaborativeAgreements
21278000
ogxi Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
15000
ogxi Property And Equipment Acquired Under Lease Obligation
PropertyAndEquipmentAcquiredUnderLeaseObligation
24000
ogxi Number Of Warrants Exercised
NumberOfWarrantsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
3.00
dei Document Type
DocumentType
10-Q
dei Entity Registrant Name
EntityRegistrantName
ONCOGENEX PHARMACEUTICALS, INC.
dei Trading Symbol
TradingSymbol
OGXI
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
12169 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-10364000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
55557 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
356097 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0183 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
16952793 shares
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
18.93
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.71
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.47
dei Entity Central Index Key
EntityCentralIndexKey
0000949858
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.8151 pure
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8300000 shares
us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
199849 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
10000 shares
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
5279000
us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-6000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3646000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
-2768000
us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-199000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
6529000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20565000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2242000
us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-63000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-14000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
80000
us-gaap Net Income Loss
NetIncomeLoss
-20559000
us-gaap Investment Income Interest
InvestmentIncomeInterest
19000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-3830000
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
28000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-6000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-596000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
36372000
us-gaap Increase Decrease In Restructuring Reserve
IncreaseDecreaseInRestructuringReserve
-582000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
24846000
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
34357000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2768000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2100000
us-gaap Depreciation
Depreciation
165000
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
25234000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1383000
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
19487000
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
22372000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
30000
us-gaap Costs And Expenses
CostsAndExpenses
44264000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7892000
ogxi Number Of Warrants Exercised
NumberOfWarrantsExercised
0 shares
ogxi Maximum Maturity Period Of Short Term Investments
MaximumMaturityPeriodOfShortTermInvestments
P1Y
us-gaap Share Based Compensation
ShareBasedCompensation
2968000
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1423000
ogxi Expiration Of Non Cancellable Operating Lease Agreement
ExpirationOfNonCancellableOperatingLeaseAgreement
2017
ogxi Revenues From Collaborative Agreements
RevenuesFromCollaborativeAgreements
21463000
ogxi Maximum Maturity Period Of Cash And Cash Equivalents
MaximumMaturityPeriodOfCashAndCashEquivalents
P90D
ogxi Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
67000
ogxi Expiration Of Operating Lease Agreement
ExpirationOfOperatingLeaseAgreement
2015-09
ogxi Common Stock Warrants Issued
CommonStockWarrantsIssued
3500000 shares
ogxi Maximum Maturity Period Of Collateralized Securities
MaximumMaturityPeriodOfCollateralizedSecurities
P1Y
ogxi Warrant Issuance Costs
WarrantIssuanceCosts
531000
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
21079310 shares
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.23
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8300000 shares
CY2014Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-4000
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4911000
CY2014Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2335000
CY2014Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-4907000
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4000
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18004000
CY2013Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-539000
CY2013Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2013Q3 us-gaap Costs And Expenses
CostsAndExpenses
20477000
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2473000
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
887000
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9586000
CY2014Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2874000
CY2014Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
700000
CY2014Q3 us-gaap Costs And Expenses
CostsAndExpenses
12045000
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2459000
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
952000
CY2014Q3 ogxi Revenues From Collaborative Agreements
RevenuesFromCollaborativeAgreements
4803000
CY2014Q3 ogxi Warrant Issuance Costs
WarrantIssuanceCosts
531000
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
14690984 shares
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2900000 shares
CY2013Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
24000
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10030000
CY2013Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
561000
CY2013Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-10054000
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
33000
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
24000
CY2013Q3 ogxi Revenues From Collaborative Agreements
RevenuesFromCollaborativeAgreements
9862000

Files In Submission

Name View Source Status
0001193125-14-389643-index-headers.html Edgar Link pending
0001193125-14-389643-index.html Edgar Link pending
0001193125-14-389643.txt Edgar Link pending
0001193125-14-389643-xbrl.zip Edgar Link pending
d778073d10q.htm Edgar Link pending
d778073dex311.htm Edgar Link pending
d778073dex312.htm Edgar Link pending
d778073dex321.htm Edgar Link pending
d778073dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
ogxi-20140930.xml Edgar Link completed
ogxi-20140930.xsd Edgar Link pending
ogxi-20140930_cal.xml Edgar Link unprocessable
ogxi-20140930_def.xml Edgar Link unprocessable
ogxi-20140930_lab.xml Edgar Link unprocessable
ogxi-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending